

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Mental health symptoms before and during COVID-19, long-term COVID-19 booster effectiveness, BA.4/BA.5 Omicron lineages and immune escape

Peer reviewed journals featured:

- Systematic reviews on:
 - Comparing mental health symptoms before and during COVID-19 [here](#), [here](#), and [here](#)
 - Paediatric emergency department visits for attempted suicide, self-harm, and suicidal ideation before and during COVID-19 [here](#) and commentary [here](#)
- A narrative review on SARS-CoV-2 infection, DNA damage, cellular senescence and inflammation [here](#) and [here](#)
- Observational studies on:
 - Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting [here](#) and associated commentary [here](#)
 - BA.4/BA.5 Omicron lineages and immune escape [here](#)
 - mRNA vaccines effect on anti-viral immunity and humoral autoimmunity [here](#)
 - Protective immunity against medically attended symptomatic Omicron BA.4, BA.5, and XBB reinfections in Singapore [here](#) and associated commentary [here](#)
 - The risk of venous thromboembolism in COVID-19 outpatients [here](#)
 - Comparison of SARS-CoV-2 variants symptoms among children in Canada [here](#)
 - Severe COVID-19 outcomes by cardiovascular risk profile in England in 2020 [here](#)
 - Omicron (B.1.1.529)-related COVID-19 sequelae in cancer patients [here](#)
 - Ambient air pollution exposure linked to long COVID among Swedish young adults [here](#)
 - Persistent COVID-19 symptoms in community-living older adults in Canada [here](#)
 - Neonatal outcomes of maternal SARS-CoV-2 infection in the UK [here](#)
 - The effectiveness of molnupiravir and nirmatrelvir–ritonavir (Paxlovid) in COVID-19 inpatients [here](#)
 - Machine learning analysis of correlates of mortality in hospitalised COVID-19 patients [here](#)

Letters and correspondence discussed:

- Estimated effectiveness of prior Omicron BA.1/BA.2 infection and booster vaccination against BA.5 infection [here](#)
- Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1 [here](#)

Pre-peer review articles featured:

- Early proximal tubular injury in COVID-19-related acute respiratory distress syndrome [here](#)
- IL-6 & IL-17 and hypertension and long-COVID sequelae in haemodialysis patients [here](#)
- SARS-CoV-2 infection with neurological symptoms and neuroimaging in paediatrics [here](#)
- Effect of dapagliflozin on COVID-19 infection and risk of hospitalisation [here](#)
- γ ' Fibrinogen levels as a biomarker of COVID-19 respiratory disease severity [here](#)
- Incidence of giant cell arteritis is associated with COVID-19 prevalence [here](#)
- Utility of COVID-19 case reports as a leading indicator for hospitalisation forecasting in the US [here](#)
- Evaluating targeted COVID-19 vaccination strategies with agent-based modelling [here](#)
- Medium-term COVID-19 scenarios as a function of immune uncertainties and chronic disease [here](#)
- Characterisation of long COVID among US Medicare beneficiaries using claims data [here](#)
- An analysis of the causes of death from COVID-19 in France in 2020 reveals its effects [here](#)

Guidance and reports

- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)

News and blogs

- Uncovering a link between COVID-19 and renal cell carcinoma [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).